Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Articles

September 11, 2015

The DAIMLER Series: Five Personal, Specific Lessons Learned for Hatch-Waxman ANDA Litigants

Bloomberg BNA Pharmaceutical Law & Industry Report

In the News

August 26, 2015

PTAB Poised To Take Up Hedge Fund Hijinks in Celgene Cases

Law360

MarkIt to Market®

August 16, 2015

MarkIt to Market – August 2015